Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PDUFA VII Already: Could Breakthrough Ideas Apply Outside Program?

Aug 26 2016

• By Derrick Gingery

Related Content

Biomarkers For Rare Diseases Get Scaled-Back Plea In New White Paper

Sep 02 2013

Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI

Jul 18 2016

Biosimilars Program Could 'Explode,' Woodcock Warns Congress

Feb 04 2016

Show Me The Money: Salaries, Red Tape Challenge FDA Recruiting

Jan 19 2015

FDA’s Woodcock Cautions Efforts To 'Legislate A New Generation Of Biomarkers'

Oct 22 2015

FDA’s Breakthrough Products: Could Patients Drive The Designations?

Mar 13 2014

CDRH's Expedited Access Pathway: 17 Devices And Counting

May 12 2016

FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds

Jul 21 2016

Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed

Jun 20 2016

Additional Topics

United States Clinical Trials Drug Review Policy Review Pathway BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window